{"id":"W2308659819","doi":"10.1038/bjc.2016.41","title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Drug Research and Development","funders":"Cancer Research UK","keywords":"PARP inhibitor; Medicine; BRCA mutation; Ovarian cancer; Tolerability; Breast cancer; Olaparib; Dosing; Cancer; Pharmacodynamics; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect; Pharmacokinetics; Biology; Poly ADP ribose polymerase; Polymerase; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002135036,0.001622053,0.001591715,0.0005037128,0.0003424478,0.0008758691,0.001142881,0.001761162,0.003661085],"category_scores_gemma":[0.001483419,0.0006941381,0.001063336,0.0005024438,0.0009529745,0.0008393623,0.0003559162,0.002873548,0.0006553537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009592003,"about_ca_system_score_gemma":0.001214961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001031995,"about_ca_topic_score_gemma":0.001450063,"domain_scores_codex":[0.9993355,0.0003216162,0.0000269948,0.000146465,0.00005286335,0.00011649],"domain_scores_gemma":[0.9989129,0.0002257646,0.0002703971,0.0001144301,0.00007500449,0.0004014359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8922567,0.0448523,0.00280206,0.0003584143,0.0006060544,0.000127392,0.0001638868,0.00123658,0.02227631,0.0001108609,0.001207896,0.03400146],"study_design_scores_gemma":[0.5734581,0.4170739,0.005614858,0.00001417371,0.000217422,0.0001475296,0.00002422627,0.0006592078,0.001859844,0.00006822345,0.0008467504,0.00001582939],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949458,0.001038914,0.0004608468,0.0001986051,0.00007936855,0.001943005,0.0005455753,0.0000679825,0.0007199648],"genre_scores_gemma":[0.9905319,0.0007247386,0.001626829,0.0004525279,0.0001499544,0.003389367,0.001548887,0.00002521299,0.001550679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003661085,"threshold_uncertainty_score":0.01224756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01034263473245879,"score_gpt":0.3000696872213802,"score_spread":0.2897270524889214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}